Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Chemomab Therapeutics
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
27 mars 2025 08h30 HE
|
Chemomab Therapeutics
Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
06 mars 2025 08h00 HE
|
Chemomab Therapeutics
Many preclinical and patient sample studies and positive Phase 2 PSC data suggest nebokitug is potentially a promising new treatment for systemic sclerosis
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
03 mars 2025 08h00 HE
|
Chemomab Therapeutics
In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
19 févr. 2025 07h00 HE
|
Chemomab Therapeutics
After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
03 févr. 2025 07h00 HE
|
Chemomab Therapeutics
Chemomab will present at the Oppenheimer Heathcare Life Sciences Conference on Feb 11 at 8 am ET and participate in 1x1 investor meetings.
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
03 déc. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC.
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
19 nov. 2024 07h00 HE
|
Chemomab Therapeutics
Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
14 nov. 2024 07h00 HE
|
Chemomab Therapeutics
In 3Q reported positive CM-101 PSC Ph 2 results. On track for 2 milestones in Q125--FDA agreement on PSC Ph 3 design and Ph 2 open label extension readout.
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
30 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will report 3Q 2024 financial results and provide a corporate update on November 14, 2024 at 7am ET.
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
15 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting